OTCMKTS:NXNN Nexeon Medsystems (NXNN) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free NXNN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Nexeon Medsystems alerts: Email Address Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Nexeon Medsystems Stock (OTCMKTS:NXNN)Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.Read More Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover NXNN Stock News HeadlinesDecember 13, 2023 | morningstar.comNexeon MedSystems Inc NXNNApril 1, 2023 | benzinga.comRelievant Medsystems Receives 2023 Gallup Exceptional Workplace AwardMarch 29, 2023 | benzinga.comFemDx Medsystems, Inc. Receives FDA Clearance For Its FalloView™ FalloposcopeJanuary 15, 2023 | bizjournals.comBattery tech company Group14 files lawsuit against British competitor NexeonOctober 16, 2022 | finance.yahoo.comNexeon MedSystems Inc. (NXNN)See More Headlines Receive NXNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nexeon Medsystems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/21/2018Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolOTCMKTS:NXNN CUSIPN/A CIKN/A Webwww.nexeonmed.com Phone(954) 837-6833FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta6.98 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. William Rosellini J.D. (Age 44)M.B.A., M.S., Chairman & CEO Comp: $2Mr. Christopher R. Miller (Age 54)Chief Financial Officer Comp: $131.75kMr. Cathal Mc FaddenVice President of OperationsDr. Austin Duke Ph.D.Chief Science OfficerKey CompetitorsAksysOTCMKTS:AKSYEcho TherapeuticsOTCMKTS:ECTEGetinge AB (publ)OTCMKTS:GNGBYHeart TronicsOTCMKTS:HRTTIMRISOTCMKTS:IMRSQView All Competitors NXNN Stock Analysis - Frequently Asked Questions How were Nexeon Medsystems' earnings last quarter? Nexeon Medsystems Inc (OTCMKTS:NXNN) released its earnings results on Monday, May, 21st. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $1.70 million. What other stocks do shareholders of Nexeon Medsystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nexeon Medsystems investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Fate Therapeutics (FATE), ObsEva (OBSV), Vaxart (VXRT), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AC Immune (ACIU), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX). How do I buy shares of Nexeon Medsystems? Shares of NXNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NXNN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexeon Medsystems Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.